Investigational drug · Phase 3
JYB1904
Also called: RPT904, ozureprubart
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
7
Any phase or sponsor naming "JYB1904"
First trial start
2024
Jun 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JYB1904", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Spontaneous Urticaria
- Perennial Allergic Rhinitis
- Immune System Diseases
- Ig-E Mediated Food Allergy
- Allergic Asthma
Approved drugs for the same conditions: Chronic hives (urticaria) · Asthma · Allergies (allergic rhinitis) · Immunology and inflammation · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "JYB1904" as an intervention, largest first.
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.Pivotal-lookingRecruiting
JemincareIndustry
NCT07402213 · 240 participants (planned) · Start Mar 9, 2026 · Primary completion Jun 7, 2027
Drug: JYB1904; Placebo+JYB1904 · For: Chronic Spontaneous Urticaria
Sites: Beijing, China
- Trial of JYB1904 Injection in Patients With Perennial Allergic RhinitisPivotal-lookingNot yet recruiting
JemincareIndustry
NCT07459452 · 135 participants (planned) · Start Apr 2026 · Primary completion Oct 2027
Drug: JYB1904; JYB1904 and 1 more · For: Perennial Allergic Rhinitis
- Trial of JYB1904 in Chronic Spontaneous Urticaria.Pivotal-lookingRecruiting
JemincareIndustry
NCT06509334 · 135 participants (planned) · Start Aug 4, 2024 · Primary completion Jul 15, 2026
Drug: JYB1904; JYB1904 and 1 more · For: Chronic Spontaneous Urticaria
Sites: Beijing, China
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyPivotal-lookingActive, not recruiting
RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
NCT07220811 · 110 participants · Start Dec 15, 2025 · Primary completion Mar 16, 2027
Drug: RPT904; RPT904 and 2 more · For: Immune System Diseases; Ig-E Mediated Food Allergy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Palo Alto, California · 37 sites in all
JemincareIndustry
NCT06438757 · 69 participants · Start Jun 19, 2024 · Primary completion Nov 20, 2025
Drug: JYB1904; Omalizumab · For: Allergic Asthma
Sites: Shanghai, China
JemincareIndustry
NCT05449535 · 56 participants · Start May 7, 2022 · Primary completion Jan 10, 2023
Drug: JYB1904; Omalizumab and 1 more · For: Healthy
Sites: Hangzhou, China
- Trial of JYB1904 Injection in Adolescent ParticipantsNot yet recruiting
JemincareIndustry
NCT07513857 · 12 participants (planned) · Start May 17, 2026 · Primary completion Jul 30, 2027
Drug: JYB1904 · For: Allergic Diseases
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single-Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double-Blind, Placebo-Controlled Study.
Shen ZW, Jin TH, Wu KQ, et al. · Clin Transl Sci 2025
Also in development for Chronic Spontaneous Urticaria
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BLU-808Phase 22 trials
Blueprint Medicines Corporation · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis
- BBT001Phase 21 trial
Bambusa Therapeutics · Chronic Spontaneous Urticaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.